- Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer program continues to show an objective response rate and median progression-free survival that substantially exceed those seen in historical control trials

- 12 of 35 (34%) patients treated per protocol at the recommended Phase 2 dose (RP2D) in combination with FOLFIRI and bevacizumab achieved a complete response or partial response (CR: 1 patient; PR: 11 patients)

- Dr. Smeal has over 20 years of industry experience developing targeted therapies and previously served as CSO of Cancer Biology at Eli Lilly and Company, and director of Pfizer Oncology Research Unit